What's in Albina Nowak, MD's pipeline?

Albina Nowak, MD has 2 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 1 in Phase 1.

Which companies overlap with Albina Nowak, MD's portfolio?

Top competitors by shared drug class: AMAG Pharmaceuticals, Inc., American Regent, Inc., Mallinckrodt, Rockwell Medical Technologies, Inc., University of Zurich.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/albina-nowak-md.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Albina Nowak, MD — Portfolio Competitive Intelligence Brief

Albina Nowak, MD pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Iron Carboxymaltose	Iron Carboxymaltose	marketed	Intravenous iron replacement agent	Iron(III) ion; transferrin and ferritin (iron-binding proteins)	Hematology

Therapeutic area mix

Hematology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

AMAG Pharmaceuticals, Inc. · 1 shared drug class
American Regent, Inc. · 1 shared drug class
Mallinckrodt · 1 shared drug class
Rockwell Medical Technologies, Inc. · 1 shared drug class
University of Zurich · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Albina Nowak, MD:

Cite this brief

Drug Landscape (2026). Albina Nowak, MD — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/albina-nowak-md. Accessed 2026-05-16.